The company has completed the patient enrolment in the P-III trial (OPTIMIZE) evaluating the efficacy and safety of OCS-01 vs vehicle in 240 patients with inflammation and pain following cataract surgery at 25 participating sites across the US
In the P-II study (SKYGGN), OCS-01 met it’s 1EPs & 2EPs in the absence of anterior chamber cells and absence of pain, achieved statistical significance for patients with OCS-01 was more effective than a vehicle, was well tolerated & the results were presented at ASCRS 2020 annual meeting and published in Clinical Therapeutics
OCS-01 is also being studied in an ongoing P-III study (DIAMOND) for DME and additional results are expected in 2023
Ref: GlobeNewswire | Image: Oculis
Related News:- Oculis Reports Results of OCS-01 in P-II (DX-211) Study for the Treatment of Diabetic Macular Edema
